fbpx Belgravia Hair Loss Blog
WE CAN HELP
Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Search Results for alopecia areata

Browse by Category

Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

A new entry has just been added to Belgravia’s Alopecia Areata Treatment Success Stories gallery.

Find out what this client had to say and see her regrowth results close up, or find out more about treating Alopecia Areata by clicking the buttons below…

(Results may vary and are not guaranteed)

VIEW SUCCESS STORY

Treatment information


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

A substantial number of study findings were published in 2019 which linked the hair loss-causing autoimmune disorder Alopecia Areata (AA) to depression.

The highly visible nature of these hair loss conditions, which can cause anything from bald spots on the scalp to complete baldness from head to toe, was thought to contribute to the psychological and emotional difficulties of those affected.

In January 2019 it was also found that, not only is depression more common in people with Alopecia Areata, but having depression may significantly increase the risk of developing alopecia.

On 2nd January 2020, in Scottish research findings published in the British Journal of Dermatology, two specific molecules – type 17 and type 2 cytokines – were shown to exhibit positive correlations with both Alopecia Areata and depression.

Dysregulation in systemic type 17 and type 2 cytokines

These researchers wanted to explore the link between mental health and Alopecia Areata, reasoning that, “Unfortunately, 60 per cent of people with AA will also develop depression, anxiety or a related condition.”

Their primary aims were to find out whether people with Alopecia Areata had different levels of molecules that had been produced by the immune system in their blood. Previous research into other autoimmune diseases, such as rheumatoid arthritis, has made connections between molecules produced by immune cells and depression.

When comparing their clinical results to those of people without Alopecia Areata, the team discovered “increased levels of multiple molecules that are produced by activated immune cells” in the Alopecia Areata group.

Complex questionnaires were then used to establish depression scores for both the participants with Alopecia Areata, and those without. When using both sets of data to establish if there was a connection between these molecules and the depression some of the AA participants had, two specific molecules stood out. These were systemic type 17 and type 2 cytokines which were notably elevated in those with AA and these levels being associated with how depressed the individual was.

As such, the team concluded: “Alopecia Areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity.”

Research part-funded by Alopecia UK

Their studies were funded by a PhD studentship grant from Medical Research Scotland, part funded by the pharmaceutical company AstraZeneca, with additional funding from the hair loss charity, Alopecia UK.

Alopecia UK is the biggest charity in the country that is dedicated to supporting those with medical hairloss. In addition to providing online resources, running local peer support groups and running many events where people who are affected by any form of Alopecia Areata – or their friends and family – can get together, it also funds research into the condition.

It is hoped this new information will help to further the medical community’s understanding of autoimmune alopecia and its relationship with depression and other mental health problems, and be of use to those developing new Alopecia Areata treatments.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


Update on ATI-50002:

In June 2018 we reported on a new clinical trial being carried out by Aclaris Therapeutics into ATI-50002, a potential eyebrow hair loss solution for people with the autoimmune disorder Alopecia Areata.

ATI-50002 is a topical janus kinase inhibitor (JAK inhibitor) and one of a number of medications the company has been developing for the treatment of the various forms of autoimmune alopecia.

On 11th December 2019 the results from this Phase 1 study were published on the clinicaltrials.gov database.

Diagram Belgravia Centre Different Types of Alopecia Areata autoimmune hair loss
Areas affected by hair loss shown in blue

However, of the data findings that were released, it appears only one person – a white male aged between 18 and 65 years – took part.

Whilst it does acknowledge that the man completed the six month study, his results are listed as ‘not specified’.

No adverse events – including serious side effects – were reported, though, as the eyebrow hair regrowth results are not provided and the trial is so small in scale, unfortunately there is little to be made of this information for now.

Despite making a ‘strong commitment’ in 2016 to the development of JAK inhibitors for the treatment of all forms of Alopecia Areata, Aclaris Therapeutics terminated its development of certain novel hair loss drugs earlier in 2019. This came after a number of disappointing trial results.

There has yet to be any official word on the trial outcome from Aclaris, with mentions of the study in the trials and pipeline sections of the pharmaceutical company’s website being notably absent.

Eyebrow hairloss is generally associated with Alopecia Totalis; this is the second most severe form of Alopecia Areata. It causes baldness of the entire scalp and can also cause additional shedding of facial hair, including brows, eyelashes, beard and nasal hair.

There are currently no MHRA-licensed nor FDA-approved Alopecia Areata treatments for either adults or children with this condition. This is why the medical and pharmaceutical communities are working hard to find appropriate solutions.

There are a number of ‘off-license’ therapies and medications which have been shown to promote hair regrowth, including immunotherapy, steroids and, where the patient is an adult with patchy hair loss of the scalp only, high strength minoxidil.

For adults with baldness that involves areas other than the scalp, and for under 16s, your GP or dermatologist should be your first port of call for assistance. For those whose hair loss is limited to sudden onset bald patches on the scalp, specialists at a dedicated hair loss clinic can provide a professional diagnosis and treatment recommendations.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


Paediatric Alopecia Areata, where the autoimmune disorder which causes sudden-onset patchy hair loss presents in children under 18 years of age, currently has no widely recommended or official treatment options.

Findings from new Serbian research involving 73 patients aged between 1 and 73 years old was published in the Dermatologic Therapy medical journal in October 2019.

Each participant had been professionally diagnosed with severe Alopecia Areata covering more than 30 per cent of their scalp, and two different therapies were trialled over the course of 6 to 12 months, to help shed light into which forms of treatment may benefit young people with this type of shedding.

Dexamethasone pulse therapy

Childrens hair loss treatment trial

This prospective study, funded by the Ministry of Education and Science of the Republic of Serbia, comprised 73 patients (aged 1–18 years) with severe Alopecia Areata where it affected more than 30 per cent of the scalp’s surface.

Of this group, 37 received 1‐day intravenous dexamethasone pulses (1‐DP), whilst 36 were administered 3‐day pulses (3‐DP) each monthly for between 6 and 12 months. All patients took part for 6 months, whilst 65 of the 73 were studied until the 12 month mark.

Dexamethasone is a corticosteroid, usually taken orally, for the treatment of inflammatory conditions, ulcerative colitis, arthritis, lupus, psoriasis and certain breathing disorders.

In addition to their allocated pulse therapy, all the participants in each group also applied topical clobetasol propionate under an occlusive plastic wrap. This is another steroid, generally used as a cream, applied topically to reduce inflammation and irritation in cases of skin conditions, including psoriasis, eczema, dermatitis, lichen planus and discoid lupus erythematosus.

Trial findings

The trial researchers considered those who achieved hair regrowth results of 50 per cent or above to be ‘good responders’ (GR).

At the six month stage, the group receiving 3‐DP was found to have more success than the 1-DP group which saw the most frequent relapses.

Those 3-DP patients whose Alopecia Areata had been present for six months or less, saw the best outcomes. The 3-DP group also came out on top at the long‐term, 12 month follow‐up, as 67 per cent had “stable results”.

what is an autoimmune disorder information alopecia areata

No patients reported any severe short‐term nor any long-term side effects from the treatment.

Interestingly, given it is well-established that people who have one autoimmune disorder are more likely to develop others, the findings state that the children who did not also have Hashimoto thyroiditis (HT) – an autoimmune disease where the immune system attacks the thyroid – were 9.8 times more likely to be a ‘good responder’ to the treatment than those with the condition.

It was therefore concluded that “Short disease duration and no HT were good prognostic factors. 3‐DP protocol is well‐tolerated, with beneficial effects and long‐lasting results in severe paediatric AA”.

Whilst these small-scale results show promise, there is still a long road of testing ahead before this type of Alopecia Areata treatment is able to be submitted for the appropriate MHRA and FDA designations it requires to be made widely available.

For now, those aged 16 and over with scalp-only Alopecia Areata can visit a hair loss clinic for a professional consultation and suitable treatment recommendations. These often involve the topical solution high strength minoxidil, which is currently MHRA-licensed and FDA-approved for the treatment of genetic hairloss.

Under 16s with any form of Alopecia Areata, or people of any age with forms which also affect other areas of the body, such as Alopecia Totalis or Alopecia Universalis, should seek advice from their GP who can refer them to a dermatologist, if necessary, to discuss hospital-based treatments such as immunotherapy.

Emotional and practical support in the form of psychodermatology and free real-hair wigs for children and young adults affected by medical hair loss, including the various forms of autoimmune alopecia, are also options worth considering.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

A new entry has just been added to Belgravia’s Alopecia Areata Treatment Success Stories gallery.

Read her Belgravia Centre review and see her regrowth results close up, or find out more about treating patchy hair loss from Alopecia Areata by clicking the relevant button below…

(Results may vary and are not guaranteed)

VIEW SUCCESS STORY

Treatment information


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Alopecia Totalis and Alopecia Universalis – the more extreme iterations of the autoimmune disorder Alopecia Areata currently have little recourse in respect to treatments or therapies with a high success rate. Whilst some options exist, they tend to produce less than stellar results.

Although no hair loss solution has been clinically-proven to treat the mild form of Alopecia, which causes patchy bald spots to the scalp only – compared to the baldness induced by its more severe phenotypes – unlike the others, normal hair regrowth tends to resume naturally within 12 months in many cases. Furthermore, Alopecia Areata treatment for this basic form generally have a higher chance of accelerating hair growth.

Diagram Belgravia Centre Different Types of Alopecia Areata autoimmune hair loss
Areas affected by hair loss shown in blue

Given how obvious these conditions are to others – with Totalis causing baldness of the head, and Universalis leading to the head and body rejecting all hair – they can have significant psychological effects on those affected, whether men, women or children.

It is for this reason, America’s answer to the UK’s MHRA – the Food and Drug Administration (FDA) – is lending its weight to the accelerated development of certain promising treatments for all forms of Alopecia Areata.

One of these is Concert Pharmaceuticals, CTP-543 – an oral JAK inhibitor drug to which it has granted Fast Track status.

Optimal CTP-543 dosage for hair regrowth now established

During the European Academy of Dermatology and Venereology (EADV) Congress in October 2019, representatives for Concert Pharmaceuticals gave an update from the on-going clinical trials into treating all forms of Alopecia Areata with CTP-543.

Data presented at the Madrid event went into more detail regarding the company’s last update and showed that researchers had managed to achieve a 50 per cent relative reduction in Severity of Alopecia Tool score in patients at 24 weeks. These participants had at least 50 per cent hair loss of the scalp prior to starting their allotted medication.

The team had been investigating various dosages of CTP-543 in order to establish the optimum, during double-blind, randomised, placebo-controlled trials with adult participants. The contenders – 4mg, 8 mg or 12 mg – were all taken twice per day for the 24 week study duration.

By the end of the study, there were some impressive results for the higher doses. Whilst 21 per cent of the 4mg group saw their SALT score improve by a minimum of 50 per cent, almost half of all patients in the 8mg group (47 per cent) and just under two-thirds of patients in the 12mg group (58 per cent) achieved this. In contrast, 9 per cent of participants in the placebo group achieved the same.

For those patients who responded to the treatment, the two larger dosages also boasted average SALT score improvements of 78 per cent in the 8mg group and 86 per cent in 12mg group.

Patient Global Impression of Improvement surveys echoed these findings, with 58 per cent of patients taking the 8mg of CTP-543 twice-daily and 78 per cent of those in the 12mg group noting they believed their hairloss to be either “much improved” or “very much improved” at the 24 week endpoint.

James V. Cassella, PhD, the study author and chief development author at Concert Pharmaceuticals – who advised that, in addition to being effective, the drug had been found to be tolerable at all these doses – told the Healio Dermatology journal, “I believe we are seeing the strongest effect of a JAK inhibitor on alopecia areata reported to date, based on the magnitude of effect that we see and the time courses of these doses. Especially with the 12-mg twice daily dosing... With this, given the players in the space, I think it sets a new bar for clinical efficacy in treating alopecia areata.”

Update on baricitinib JAK inhibitor trials

This news follows an announcement from pharmaceutical company, Eli Lilly and Company, which recently advised it has ‘reached a milestone’ in its testing of drug LY3009104, also known as the JAK inhibitor baricitinib, for the treatment of mild to severe forms of Alopecia Areata.

Exploratory trials into using baricitinib to treat patchy hair loss to total baldness caused by the various types of Alopecia Areata, have been underway since at least 2015. They are now entering Phase 3 testing for the treatment of both adults and children.

One aspect it is likely the Lilly team is working on, is reducing the current adverse events profile of baricitinib (brand name: Olumiant), as it carries some pretty serious potential side effect warnings at present in its use as a rheumatoid arthritis medication.

what is an autoimmune disorder information alopecia areata

The patient information leaflet and Olumiant website both state the drug ‘may cause serious side effects.’ These range from ‘serious infections, including tuberculosis (TB)’ and potentially life-threatening ‘blood clots’, to ‘cancer and immune system problems’.

‘Olumiant may increase your risk of lymphoma and other cancers, including skin cancers,’ states the manufacturer’s warning.

Similar serious side effect profile concerns were raised with regard to the JAK inhibitor tofacitnib (brand name: Xeljanz) when that was first discovered to have beneficial hair regrowth effects for people with autoimmune alopecia.

As part of its development, researchers have been exploring topical options of the drug in order to help reduce side effects found in the systemic version.

Interestingly, Incycte, another pharmaceutical company with whom Lilly is currently partnering to investigate baricitinib as an atopic dermatitis treatment, has previously carried out clinical trials into oral baricitinib.

These are the latest updates from the race to develop the first FDA-approved Alopecia Areata, Totalis and Universalis treatments and we will add more information to the Belgravia blog as addtional news is released.

In the meantime, if you are concerned about sudden hair fall, if you are an adult with hair loss from the scalp only, a consultation with hair loss specialist can provide you with a professional diagnosis and personalised treatment recommendations. If you are an adult losing hair from your scalp and/or other parts of your body, including your face, or if you are under 16 years of age, we recommend speaking to your doctor who may then refer you on to a dermatologist.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


Gut health is not just a hot wellness trend.

The gastrointestinal tract has long been considered the root of good health in Asian medicine, whilst the Western world only started to show significant medical interest over the past 10 years or so.

This is despite the founder of modern medicine, the Greek physician Hippocrates who died in 370BC, famously stating “all disease begins in the gut”.

Researchers in Spain recently conducted a cross-sectional study to establish whether gut microbiota played a role in the autoimmune disorder, Alopecia Areata. Specifically, they were looking for links to its most severe phenotype, Alopecia Universalis.

stomach gut health

Whereas the mild form of Alopecia Areata presents as patchy hair loss to the scalp only, Alopecia Universalis causes complete baldness from head-to-toe.

All forms can be distressing as the hair growth cycle becomes suspended, resulting in sudden hairloss with the length of time this will remain ‘stuck’ being unpredictable.

There are Alopecia Areata treatments available for the scalp-only type, which will often see spontaneous hair regrowth resume within 12 months, too. However, for the more extensive iterations, including Alopecia Universalis, treatments tend to be less successful and the conditions are generally on-going. There are currently no MHRA-licensed nor FDA-approved treatments for Alopecia Areata, though many are in development.

Although the underlying mechanisms that cause all types of autoimmune alopecia are still unknown, various triggers have been identified. These include sudden shock and trauma, allergies, hormones and a genetic element is also suspected.

Possible bacterial biomarkers

A team comprising researchers from various medical institutions in Madrid, compared the gut health of 15 patients with Alopecia Universalis and 15 healthy control participants.

In the study report published in the Journal of the European Academy of Dermatology and Venereology on 16th August 2019, the methodology is explained: “Gut microbiome of the study subjects was analysed by sequencing the 16SrRNA of stool samples. We searched for bacterial biomarkers of alopecia universalis using the linear discriminant analysis effect size (LEFse) tool.”

Of the 30 subjects, 46.6 per cent were women and 53.4 per cent were male and no statistically significant difference was noted in gut bacteria based on gender.

Normal Hair Growth Cycle versus Hair Growth in Alopecia Areata

However, the team noted that an “enriched presence (LDA SCORE > 2) of Holdemania filiformis, Erysipelotrichacea, Lachnospiraceae, Parabacteroides johnsonii, Clostridiales vadin BB60 group, Bacteroides eggerthii and Parabacteroides distasonis” was seen in the participants with Alopecia Universalis.

Furthermore, they advised that a “predictive model based on the number of bacterial counts of Parabacteroides distasonis and Clostridiales vadin BB60 group correctly predicted disease status in 80% of patients…”

It was concluded that, although this study showed that Alopecia Universalis “does not seem to affect broadly gut microbiota structure” more research was needed as there were a number of bacterial biomarkers found which were associated with the disease and these may be involved in the condition’s pathophysiology. Alternatively, their presence could be used to assist in diagnosing the disorder, which can affect men, women and children of any age, race or hair type.

Novartis looking to revist alopecia areata treatment research?

Pharmaceutical company, Novartis contributed to the financing of this Spanish study. This may indicate that the Swiss multinational is considering revisiting a foray into developing Alopecia Areata hair loss solutions.

In 2015 Novartis started clinical trials into its biological, interleukin-17A-blocking drug, secukinumab – which goes under the brand name Cosentyx – to determine whether it could be a potential treatment for Alopecia Areata.

At present – October 2019 – however, there is no mention of this trial, nor any other research into Alopecia Areata in any of its forms, in the company’s pipeline reports. Should any new information come to light on this, we will publish updates here on the Belgravia blog.

In the meantime, adults concerned about sudden hair fall from the scalp should contact a dermatologist or hair loss specialist, whilst children or those with shedding in other areas of the face or body, should speak to their doctor as a first port of call.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


On 12th September 2019 it was made official that Aclaris Therapeutics Inc has dropped out of the race to develop the first JAK inhibitor-based treatment for all forms of Alopecia Areata.

The company’s official clinical trial registration for the open label study of its novel topical and oral hair loss solution, known as ATI-502, was updated with the news that it has decided to end its investigations.

This follows disappointing performance reports after ATI-502 Phase 2 trials for each iteration of autoimmune alopecia, from the mild scalp-only form, through to the more extensive Alopecia Totalis and Alopecia Universalis.

Portfolio of exclusive patents

Aclaris has been developing these janus kinase inhibition-based drugs since around 2016, when they announced a ‘strong commitment’ to this particular approach.

Aclaris Therapeutics

The company worked closely with Columbia University in America, which made some of the initial discoveries relating to how JAK inhibitors can be used to treat Alopecia Areata, and acquired many exclusive patent rights to a number of different members of this suite of drugs, licensed from both the Columbia Trustees and others.

What will happen to this impressive portfolio of patents remains to be seen.

Although the company also explored ATI-502 for the treatment of Male Pattern Baldness and Female Pattern Hair Loss, and developed a separate ATI-501 oral candidate for Alopecia Areata, its website suggests these also stalled at the Phase 2 stage.

Pfizer and Concert Pharmaceuticals battling it out

Concert Pharmaceuticals

With Aclaris now out of the picture, and the race to bring the first ever Alopecia Areata, Totalis and Universalis treatment to market that is FDA-licensed (and hopefully MHRA-approved, the MHRA being the UK equivalent of the FDA – America’s medical regulatory board) reaching its latter stages, two clear competitors have emerged.

Pfizer and Concert Pharmaceuticals are now the two leading pharmaceutical companies left with hats in this particular hair loss ring, and both have promising-looking propositions.

Pfizer

Pfizer is currently in Phase 3 trials for JAK inhibitor treatments for both adults and adolescents, from 12 years of age, with all forms of Alopecia, whilst Concert is preparing to enter the Phase 3 stage, having recently announced positive findings from its Phase 2 trials of over 18s.

The FDA is working closely with both companies, having awarded Concert Pharmaceuticals Fast Track status for its CTP-543 candidate, and granted Pfizer Breakthrough status for its PF-06651600 drug.

There are currently no officially recognised treatments for this condition and, whilst the scalp-only form has both Alopecia Areata treatment course options and tends to right itself naturally within up to 12 months, Alopecia Totalis and Universalis in adults and all forms in children have little in the way of safe and effective therapies available – yet.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


There are many well-established links between physical health and mental health; even on a basic level, the endorphins released as a result of exercise are known to improve our mood, our sleep and reduce stress – a known culprit behind many hair loss conditions.

Now an Australian study has looked specifically at the relationship between the effects of physical activity levels and the psychological well-being of people with hair loss caused by the chronic autoimmune disorder Alopecia Areata (AA).

exercise mental health feet trainers sneakers physical activitiy happy

This research follows a number of reports detailing how people with any form of Alopecia Areata have a higher risk of developing anxiety and depression.

Patients completed questionnaires

The study authors, from various institutions across Melbourne, note the specificity of this study was necessary due to the fact that “physical activity (PA) has been associated with better mental health outcomes in diverse populations [however] the association in individuals with AA has not been established. The aim of this study was to examine the associations between PA and mental health outcomes in individuals with AA to inform intervention strategies for this specific population.”

The team’s methodology involved a cross-sectional study conducted among 83 participants aged 40.95 ± 13.24 years who had lost more than half the hair on their scalp.

Each volunteer completed authorised International Physical Activity Questionnaire-Short Form (IPAQ-SF) and the Depression and Anxiety Stress Scale (DASS-21) questionnaires before their results were analysed to determine associations between physical activity levels and mental health outcomes.

When analysing the findings, researchers found that 81.9 per cent of these respondents did not meet guidelines – presumably Australian government guidelines though this is not stated – for physical activity.

Less physical activity linked to depression and anxiety

Results showed a clear correlation between the participants who did not meet physical activity guidelines and an increased propensity towards severe depression, moderate anxiety and mild stress.

Therefore, researchers concluded this suggests “increased PA participation in AA individuals with severe hair loss is associated with improved mental health status. Intervention efforts for this specific population should consider barriers and enablers to PA participation as they face challenges that differ from the general population.”

Life wait for storm dance in the rain quote inspirational

In the UK, the NHS gives the following advice on the amount of exercise adults aged 19 to 64 need to do, per week, in addition to advising all long periods of sitting are broken up with light activity:

“…at least 150 minutes of moderate aerobic activity such as cycling or brisk walking every week and strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)
Or: 75 minutes of vigorous aerobic activity such as running or a game of singles tennis every week and strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)
Or: a mix of moderate and vigorous aerobic activity every week – for example, 2 x 30-minute runs plus 30 minutes of brisk walking equates to 150 minutes of moderate aerobic activity and strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)…”

Group classes or team sports can also provide a valuable sense of camaraderie, as a number of amateur and professional sports people with Alopecia Areata have found. Famous examples include English rugby player Heather Fisher, footballer Jonjo Shelvey, basketball player Charlie Villanueva and former Olympian cyclist, Joanna Rowsell-Shand, who are all bald due to the more extreme Alopecia phenotypes.

These include Alopecia Totalis and Alopecia Universalis and, although Alopecia Areata treatment is possible for the scalp-only form, these more extensive iterations – which cause baldness to the head and from head-to-toe, respectively – currently have low success-rates for the limited hospital-based treatments available.

Whilst becoming an Olympic-level gold-medallist isn’t feasible for everyone, small steps every day can be beneficial to both mind and body – and especially so to those already known to be more prone to mental health issues.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories


A case study published in the Dermatology Practical & Conceptual journal has suggested medical professionals should consider Alopecia Areata a potential warning sign of other autoimmune disorders.

Alopecia Areata presents as patchy hair loss to the scalp, though in its more severe phenotypes it can also cause baldness to the entire head and/or body.

All forms are known to be autoimmune in nature and it is well-established that people with any autoimmune disorder are more likely to develop others.

Twins with Alopecia Areata and Thyroiditis

Hair loss, itchy scalps and thyroiditis

The study letter references a particular need to check for potential thyroid issues as Alopecia Areata may be a marker for issues such as autoimmune thyroiditis.

In this letter, published online on 31st July 2019, its authors, from the Dermatology Unit in the Department of Health Sciences of Magna Graecia University in Catanzaro, Italy, recount their experience with two identical 15 year old female twins (pictured).

Both developed Alopecia Ophiasis – a form of Alopecia Areata that causes a ‘snaking’ band of hairloss around the hairline. The first twin’s alopecia started at 4 years old; she then underwent treatment using systemic and topical corticosteroids from 14 years of age. The second twin presented with Alopecia Areata at age 14. Each twin’s hair loss is also accompanied by what the investigators refer to as “occasional itch”.

Following consultations and blood work, the researchers then diagnosed them both with autoimmune thyroiditis, with both showing “very high” autoantibody levels.

The case study letter advises, “treatment with oral betamethasone 2 mg/day was started for both twins for 1 month when they were 14 years old. It was then reduced to 2 mg twice a week in association with vasodilatory and antiseptic lotions of the scalp for 2 months. This therapy led to a partial remission of dermatological manifestations in both patients. An endocrinological consultation was also recommended to better evaluate thyroid malfunctioning.”

Links between Alopecia Areata and thyroid disorders

The Italian team’s personal observations led them to a conclusion which is essentially a warning to their peers that Alopecia Areata may be a biomarker for thyroid issues. They write:

Diagram Belgravia Centre Different Types of Alopecia Areata autoimmune hair loss
Areas affected by hair loss shown in blue

“Several studies have revealed a high prevalence of thyroid disorders in patients with AA. Screening for autoimmune thyroiditis and thyroid function should be done in all patients with these cutaneous disorders for the early identification of this disease…

Based on the literature data, which suggest a common activation of different immune patterns, and on the data obtained by our clinical case, we can say that AA should be considered a warning manifestation for other distinct diseases such as ones that affect the thyroid. In this unusual case, a genetic study to support the relationship between AA and autoimmunity may be useful.”

As they mention, this case study’s findings back those of larger scale research that has also established links between Alopecia Areata and autoimmune-based thyroid problems. These include Grave’s disease and Hashimoto’s thyroiditis.

Korean studies from 2017 found that, in a nationwide review, patients with Alopecia Areata were more likely to develop Graves’ disease or Hashimoto thyroiditis than those who did not. Additionally, people with the most severe forms of Alopecia Totalis or Alopecia Universalis, had a notably increased risk of developing either of these thyroid conditions.

Additional American research, released in October 2017, also suggested that specifically children should be screened for thyroid disorders if they present with Alopecia Areata.

Hair regrowth from the scalp-only form of Alopecia Areata will generally occur naturally within 12 months, though this is not usually the case for the more extensive forms. In either case, whether you intend to undergo Alopecia Areata treatment or not, it is worthwhile alerting your GP to the fact that you have developed this condition due to its potential ramifications on other areas of your health.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.

Related Stories